Shopping Cart
- Remove All
- Your shopping cart is currently empty
NAD+ (β-Nicotinamide Adenine Dinucleotide) is a coenzyme composed of ribosylnicotinamide 5'-diphosphate coupled to adenosine 5'-phosphate by pyrophosphate linkage. It is found widely in nature and is involved in numerous enzymatic reactions in which it serves as an electron carrier by being alternately oxidized (NAD+) and reduced (NADH).
Pack Size | Price | Availability | Quantity |
---|---|---|---|
500 mg | $41 | In Stock | |
1 g | $48 | In Stock |
Description | NAD+ (β-Nicotinamide Adenine Dinucleotide) is a coenzyme composed of ribosylnicotinamide 5'-diphosphate coupled to adenosine 5'-phosphate by pyrophosphate linkage. It is found widely in nature and is involved in numerous enzymatic reactions in which it serves as an electron carrier by being alternately oxidized (NAD+) and reduced (NADH). |
In vitro | METHODS: HEK293 cells were treated with FK866 (2 µM) and NAD+ (100 µM) for 48 h. Metabolic activity was determined by MTT Assay. RESULTS: Addition of FK866 to the culture medium resulted in rapid depletion of intracellular NAD stores and inhibition of the metabolic activity of NADPH-dependent dehydrogenase. When supplemented with additional NAD+, the metabolic activity of the cells returned to control levels. [1] METHODS: Isolated microvessels from rat retina were treated with NAD+ (0-1000 nM) for 0-24 h. Cell death was detected using trypan blue dye. RESULTS: Exposure to NAD+ increased microvascular cell death in a dose-dependent manner, with the half-maximum effective concentration of NAD+ being approximately 2 nM. assessment of the time course of NAD+-induced vascular toxicity showed that cell death was detected after 16 h of NAD+ exposure. [2] |
In vivo | METHODS: To study the effects on ischemia/reperfusion (I/R) injury, NAD+ (5-20 mg/kg) was injected intravenously into Wistar rats with myocardial ischemia/reperfusion. RESULTS: Injections of 10-20 mg/kg NAD+ dose-dependently reduced I/R-induced myocardial infarction, with a dose of 20 mg/kg NAD+ reducing infarction by approximately 85%. Injection of NAD+ significantly reduced I/R-induced apoptotic cardiac injury. [3] |
Alias | β-Nicotinamide Adenine Dinucleotide, β-NAD, β-DPN, DPN, Cozymase |
Molecular Weight | 663.43 |
Formula | C21H27N7O14P2 |
Cas No. | 53-84-9 |
Smiles | O.NC(=O)c1ccc[n+](c1)[C@@H]1O[C@H](COP([O-])(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](O)[C@H]1O |
Relative Density. | Ca. 1.6 g/cm3. Temperature:20 °C. |
Storage | store at low temperature,keep away from direct sunlight,store under nitrogen | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||||||||||||
Solubility Information | H2O: 40 mg/mL (60.29 mM ), Sonication is recommended. | ||||||||||||||||||||||||||||||
In Vivo Formulation | 5% DMSO+95% Saline: 0.33 mg/mL (0.5 mM), In vivo: Please add co-solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.![]() | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
H2O
|
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.